ImMucin + sargramostim

ImMucin + sargramostim is a combination immunotherapeutic regimen investigated as a cancer vaccine approach, primarily for hematologic and solid tumors. **ImMucin** is a therapeutic peptide cancer vaccine targeting the MUC1 glycoprotein, overexpressed and abnormally glycosylated in a range of cancers, aiming to induce a robust T-cell mediated anti-tumor response. **Sargramostim** is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used as an immune adjuvant to enhance vaccine efficacy by promoting dendritic cell maturation and antigen presentation. As a combination, ImMucin serves as the antigenic stimulus while sargramostim acts as an immune modulator and adjuvant, enhancing both innate and adaptive anti-tumor responses. The combination is primarily under investigation for various cancers, including hematologic malignancies and solid tumors, and is not yet approved for any indication. Sargramostim’s broader indications include acceleration of hematopoietic recovery post-bone marrow suppression and as an adjunct in immunotherapy settings, but its use specifically with ImMucin is investigational.

Brand names

Leukine

Other names

GM-CSFrecombinant human granulocyte-macrophage colony-stimulating factorrhu GM-CSF